Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2004-06-02
2009-06-02
Rawlings, Stephen L (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C530S300000, C530S350000, C435S007100, C435S007800, C435S034000, C435S320100, C435S325000, C536S023500, C436S501000, C424S277100
Reexamination Certificate
active
07541035
ABSTRACT:
Immunogenic T-cell receptor gamma Alternate Reading Frame Protein (TARP) polypeptides are disclosed herein. These immunogenic TARP polypeptides include nine consecutive amino acids of the amino acid sequence set forth as SEQ ID NO: 9 and do not comprise amino acids 1-26 or amino acids 38-58 of SEQ ID NO: 1. Several specific, non-limiting examples of these polypeptides are set forth as SEQ ID NOs: 3-7. Nucleic acids encoding these polypeptides, and host cells transfected with these nucleic acids, are also disclosed. Methods of using these polypeptides, and polynucleotides encoding these polypeptides, for the treatment of breast and prostate cancer are also disclosed.
REFERENCES:
patent: 5763219 (1998-06-01), Keyomarsi
patent: 6326471 (2001-12-01), Kokolus et al.
patent: 6387888 (2002-05-01), Mincheff et al.
patent: 6500641 (2002-12-01), Chen et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: WO 99/61068 (1999-12-01), None
patent: WO 01/04309 (2001-01-01), None
patent: WO 02/077012 (2002-10-01), None
patent: WO 03/009814 (2003-02-01), None
Holmes (Expert Opinion on Investigational Drugs. 2001; 10: 511-519).
Daniel et al. (Virology. 1994 202: 540-549).
Schirle et al. (J. Immunol. Methods. 2001; 257: 1-16).
Fisk et al. (J. Immunother. Emphasis Tumor Immunol. Nov. 1995; 18 (4): 197-209).
Huard et al. (Int. Immunol. 1997; 9 (11): 1701-1707).
Ruppert et al. (Cell. Sep. 10, 1993; 74 (5): 929-937).
Valmori et al. (J. Immunol. 1998; 161: 6956-6962).
Guichard et al. (J. Med. Chem. 2000; 43: 3803-3808).
Andersen et al. (Tissue Antigens. Jun. 2000; 55 (6): 519-531).
Feltkamp et al. (Mol. Immunol. Dec. 1994; 31 (18): 1391-1401).
van der Burg et al. (J. Immunol. May 1, 1996; 156 (9): 3308-3314).
Valmori et al. (Journal of Immunology. 1998; 160: 1750-1758).
Verma et al. (Nature 1997, 389: 239-242).
Amalfitano et al. (Current Gene Therapy 2002, 2: 111-133).
Pandha et al. (Current Opinion in Investigational Drugs 2000; 1 (1): 122-134).
Saijo et al. (Cancer Sci. Oct. 2004; 95 (10): 772-776).
Kelland (Eur. J. Cancer. Apr. 2004; 40 (6): 827-836).
Bergers et al. (Current Opinion in Genetics and Development. 2000; 10: 120-127).
Wang et al. (Exp. Opin. Biol. Ther. 2001; 1 (2): 277-290).
Bins et al. (J. Immunother. Feb.-Mar. 2007; 30 (2): 234-239).
Cox et al. (Science. 1994; 264: 716-719).
Arceci (Journal of Molecular Medicine. 1998; 76: 80-93).
Lee et al. (Journal of Immunology. 1999; 163: 6292-6300).
Zaks et al. (Cancer Research. 1998; 58: 4902-4908).
Gao et al. (Journal of Immunotherapy 2000; 23: 643-653).
Hu et al. (Cancer Research. 1996; 56: 2479-2483).
Jaeger et al. (International Journal of Cancer. 1996; 66: 162-169).
Mukherji et al. (Proceedings of the National Academy of Science USA. 1995; 92: 8078-8082).
Bocchia et al. (Haematologica. 2000; 85; 1172-1206).
Altuvia et al., “A Structure-Based Algorithm to Predict Potential Binding Peptides to MHC Molecules with Hydrophobic Binding Pockets,”Human Immunol.58:1-11 (1997).
Bodey et al., “Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy,”Anticancer Research20:2665-2676 (2000).
Boon et al., “Toward a Genetic Analysis of Tumor Rejection Antigens,”Advances in Cancer Research58:177-211 (1999).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerence to Amino Acid Substitutions,”Science247:1306-1310 (1990).
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,”J. Cell Biology111:2129-2138 (1990).
Carlsson et al., “Generation of Cytotoxic T Lymphocytes Specific for the Prostate and Breast Tissue Antigen TARP,”The Prostate61:161-170 (2004).
Cheng et al., “Characterization of the Androgen-Regulated Prostate-Specific T Cell Receptor γ-Chain Alternate Reading Frame Protein (TARP) Promoter,”Endocrinology144(8):3433-3440 (2003).
Corman et al., “Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 cells,”Clin Exp Immunol.114(2):166-172 (1998) (Abstract Only).
Correale et al., “In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived from Prostate-Specific Antigen,”J. Natl. Cancer Institute89(4):293-300 (1997).
Critchfield et al., “The Future of DNA Diagnostics,”Disease Markers15:108-111 (1999).
Davodeau et al., “Secretion of Disulfide-linked Human T-cell Receptor γδ Heterodimers,”The Journal of Biological Chemistry,268(21):15455-15460 (1993).
Denkberg et al., “Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies,”J. Immunol.169(8):4399-4407 (2002) (Abstract Only).
Essand et al., “High expression of a specific T-cell receptor γ transcript in epithelial cells of the prostate,”Proc. Natl. Acad. Sci. USA,96:9287-9292 (1999).
Ezzell, “Cancer ‘Vaccines’: An Idea Whose Time Has Come?”J. NIH Research7:46-49 (1995).
Greenspan et al., “Defining epitopes: It's not as easy as it seems,”Nature Biotechnology17:936-937 (1999).
Greten et al., “Peptide-β2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes,”J. Immunol. Methods271(1-2):125-135 (2002) (Abstract Only).
Guichard et al., “Melanoma Peptide MART-1(27-35) Analogues with Enhanced Binding Capacity to the Human Class I Histocompatibility Molecule HLA-A2 by Introduction of a β-Amino Acid Residue: Implications for Recognition by Tumor-Infiltrating Lymphocytes,”J. Med. Chem.43:3803-3808 (2000).
Gura, “Systems for Identifying New Drugs are Often Faulty,”Science278:1041-1042 (1997).
Hawkins et al., “PEDB: the Prostate Expression Database,”Nucleic Acids Research,27(1):204-208 (1999).
Heiser et al., “Introduction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplfied Tumor RNA,”J. Immunol.166:2953-2960 (2001).
Huang et al., “Prostate cancer expression profiling by cDNA sequencing analysis,”Genomics,59(2):178-186 (1999) (EMEST Database Entry AI557112, Accession No. AI557112).
Johansen et al., “Peptide binding to MHC class I is determined by individual pockets in the binding groove,”Scand J. Immunol.46(2):137-146 (1997) (Abstract Only).
Kondo et al., “Prominent Roles of Secondary Anchor Residues in Peptide Binding to HLA-A24 Human Class I Molecules,” 155:4307-4312 (1995).
Lazar et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,”Molecular and Cellular Biology8(3):1247-1252 (1988).
Lim et al., “Selection of Peptides that Bind to the HLA-A2.1 Molecule by Molecular Modelling,” Molecular Immunol. 33(2):221-230 (1996).
Lu et al., “Recognition of Prostate Tumor Cells by Cytotoxic T Lymphocytes Specific for Prostate-specific Membrane Antigen,”Cancer Research62:5807-5812 (2002).
Maeda et al., “The T Cell Receptor γ-Chain Alternate Reading Frame Protein (TARP), a Prostate-specific Protein Localized in Mitochondria,”J. Biol. Chemistry279(3):24561-24568 (2004).
Nussbaum, et al., “Using the World Wide Web for predicting CTL epitopes,”Current Opinion in Immunology15:69-74 (2003).
Oh, et al., “Human CTLs to Wild-Type and Enhanced Epitopes of a Novel Prostate and Breast Tumor-Associated Protein, TARP, Lyse Human Breast Cancer Cells,”Cancer Research64:2610-2618 (Apr. 1, 2004).
Ruppert et al., “Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules,”Cell Press137:929-937 (1993).
Sarobe et al., “Enhanced In Vitro Potency and In Vivo Immunogenicity of a CT
Berzofsky Jay A.
Oh SangKon
Pastan Ira
Klarquist & Sparkman, LLP
Rawlings Stephen L
The United States of America as represented by the Secretary of
LandOfFree
Immunogenic peptides for the treatment of prostate and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic peptides for the treatment of prostate and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic peptides for the treatment of prostate and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4103665